Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study.

Background

While acute kidney injury (AKI) is a common complication in COVID-19, data on post-AKI kidney function recovery and the clinical factors associated with poor kidney function recovery is lacking.

Methods

A retrospective multi-centre observational cohort study comprising 12,891 hospitalized patients aged 18 years or older with a diagnosis of SARS-CoV-2 infection confirmed by polymerase chain reaction from 1 January 2020 to 10 September 2020, and with at least one serum creatinine value 1-365 days prior to admission. Mortality and serum creatinine values were obtained up to 10 September 2021.

Findings

Advanced age (HR 2.77, 95%CI 2.53-3.04, p < 0.0001), severe COVID-19 (HR 2.91, 95%CI 2.03-4.17, p < 0.0001), severe AKI (KDIGO stage 3: HR 4.22, 95%CI 3.55-5.00, p < 0.0001), and ischemic heart disease (HR 1.26, 95%CI 1.14-1.39, p < 0.0001) were associated with worse mortality outcomes. AKI severity (KDIGO stage 3: HR 0.41, 95%CI 0.37-0.46, p < 0.0001) was associated with worse kidney function recovery, whereas remdesivir use (HR 1.34, 95%CI 1.17-1.54, p < 0.0001) was associated with better kidney function recovery. In a subset of patients without chronic kidney disease, advanced age (HR 1.38, 95%CI 1.20-1.58, p < 0.0001), male sex (HR 1.67, 95%CI 1.45-1.93, p < 0.0001), severe AKI (KDIGO stage 3: HR 11.68, 95%CI 9.80-13.91, p < 0.0001), and hypertension (HR 1.22, 95%CI 1.10-1.36, p = 0.0002) were associated with post-AKI kidney function impairment. Furthermore, patients with COVID-19-associated AKI had significant and persistent elevations of baseline serum creatinine 125% or more at 180 days (RR 1.49, 95%CI 1.32-1.67) and 365 days (RR 1.54, 95%CI 1.21-1.96) compared to COVID-19 patients with no AKI.

Interpretation

COVID-19-associated AKI was associated with higher mortality, and severe COVID-19-associated AKI was associated with worse long-term post-AKI kidney function recovery.

Funding

Authors are supported by various funders, with full details stated in the acknowledgement section.

Informations de copyright

© 2022 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Dr Hanauer reported having developed an electronic resource of clinical synonyms, EMERSE, that is licensed by the University of Michigan and receiving a portion of the licensing fees for this resource outside the submitted work. Dr Omenn reported being an early investor and serving on the board of Angion Biomedica Corporation, New York, which has conducted clinical trials of drug candidates for overcoming acute kidney injury following cardiopulmonary surgery or kidney transplantation. The former was terminated early based on unsatisfactory efficacy/adverse effects assessment; the latter had insufficient benefit to warrant proposing a Phase III trial. The company is moving in other directions, to be determined. No further work on kidney is anticipated. Dr Holmes disclosed participation as an NIH/NIDDK T2 Coach R01DK113189. Dr Malovini disclosed being a shareholder of Biomeris s.r.l. Dr Bellazzi reported receiving honoraria from Pfizer, and disclosed being a shareholder of University of Pavia spin-off Biomeris. Dr Klann reports consulting fees from i2b2 tranSMART foundation, for work to enhance open-source data warehouse platform. He reports no direct relationship to this work, except that the data model for analysis in this manuscript was inspired by this platform.